VIATRIS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
VIATRIS INC. (VTRS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 5.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-26
- VIATRIS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 5.50%, a 50.89% decline from fiscal 2023.
- VIATRIS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 11.20%.
- VIATRIS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -6.70%.
- VIATRIS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -109.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 5.50% 10-K · filed 2026-02-26 | |
| 2023-12-31 | 11.20% 10-K · filed 2026-02-26 | |
| 2022-12-31 | -6.70% 10-K · filed 2025-02-27 | |
| 2021-12-31 | -109.70% 10-K · filed 2024-02-28 | -2.80% 10-K · filed 2022-02-28 |
| 2020-12-31 | -35.50% 10-K · filed 2023-02-27 | 5.80% 10-K · filed 2021-03-01 |
| 2019-12-31 | 7.70% 10-K · filed 2022-02-28 | |
| 2018-12-31 | 0.00% 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |